Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03052257 · ClinicalTrials.gov registry record · NA

Improve Glaucoma Medication Adherence

A NA study, sponsored by VA Office of Research and Development.

Completed
Registry status
NA
Development phase
200
Enrollment target

NCT03052257: Completed NA study, sponsored by VA Office of Research and Development.

NCT03052257 is a NA study that has completed, run by VA Office of Research and Development. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03052257, a NA study, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
NA
Development phase
200 participants
Enrollment target

Study Summary

The proposed study is a randomized controlled trial enrolling Veterans with medically treated glaucoma who report less than 100% adherence to the prescribed glaucoma therapy. Participants will be randomized to receive either a one-on-one session with a member of the research team discussing the disease process and strategies for administering eye drops (intervention) or a one-on-one session with a member of the research team discussing general eye health (control). All participants will be provided with a "smart bottle" to house their glaucoma medications. The smart bottle records the date and time that the bottle is opened. For participants in the intervention arm only, a reminder function will be activated. The proportion or prescribed doses taken according to the monitor will be compared for the two groups.

Interventions

  • BEHAVIORAL Educational - glaucoma
  • BEHAVIORAL Dose monitoring and reminder
  • BEHAVIORAL Educational - general
  • BEHAVIORAL Dose monitoring

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2017-08-09
Est. Completion 2021-03-01
Phase NA

Sponsor

VA Office of Research and Development

1,668 total trials

What the Registry Record Tells You About NCT03052257

The ClinicalTrials.gov registry entry for NCT03052257 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Educational - glaucoma is the first listed.

NCT03052257 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03052257 about?

NCT03052257 is a clinical study titled "Improve Glaucoma Medication Adherence". The proposed study is a randomized controlled trial enrolling Veterans with medically treated glaucoma who report less than 100% adherence to the prescribed glaucoma therapy. Participants will be randomized to receive either a one-on-one session with a member of the research team discussing the dise...

What is the current status of trial NCT03052257?

This trial is currently completed. It is a NA study. The enrollment target is 200 participants. The study started on 2017-08-09. Estimated completion is 2021-03-01.

What interventions are being tested in trial NCT03052257?

The interventions under investigation include: Educational - glaucoma (BEHAVIORAL), Dose monitoring and reminder (BEHAVIORAL), Educational - general (BEHAVIORAL), Dose monitoring (BEHAVIORAL).

Who is sponsoring clinical trial NCT03052257?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.